
Drug de-escalation in lung cancer: are we nearly there yet?
While strategies for drug de-escalation continue to be actively pursued, some challenges including insufficient funding of research still limit their applicability
While strategies for drug de-escalation continue to be actively pursued, some challenges including insufficient funding of research still limit their applicability
Phase III data in metastatic NSCLC support an alternative route of administering immunotherapy, which may have an impact on patients’ preferences and cancer care costs
Results from the ETOP AMAZE-lung and COCOON trials show some promise to improve safety and reduce skin adverse events
Studies evaluate the efficacy and safety of promising agents including adagrasib and fulzerasib
Results from two trials could expand current options for patients with EGFR or HER2-activating mutations progressing on tyrosine kinase inhibitors
According to Heine H. Hansen Award winner, Prof. Keith Kerr, pathologists can help translate scientific understanding into clinical practice
Detecting ctDNA and a simple four-component scoring system showed some predictive value, but require prospective validation
A model implemented by a non-profit organisation exemplifies how virtual consultation and follow-up of patients with rare cancer can facilitate continuity of care
Newly presented phase III trial and real-world findings reassure on the use of the gamma secretase inhibitor
Researchers’ confidence is growing, but the quality of the data generated may still represent a challenge
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.